The IOM’s Action Collaborative DIGITizE (Displaying and Integrating Genetic Information Through the EHR) has posted its first implementation guide, based extensively on the terms established for pharmacogenetic phenotypes by the PGRN’s CPIC. The DIGITizE group will be developing additional use cases to facilitate the incorporation of genetic testing into clinical medicine.
David A. Flockhart, M.D., Ph.D., an internationally renowned researcher and physician who transformed care for patients by personalizing treatments and making medications safer and more effective, died on Thanksgiving Day (November 26) in his home in Indianapolis surrounded by his family. He was 63.
Dr. Flockhart was diagnosed a little more than a year ago with glioblastoma multiforme, an advanced type of brain cancer. Ever the teacher, he shared his personal experience with the disease through radio interviews, public forums and other avenues, addressing important issues such as access to care and inefficiencies in the health care system that place an undue burden on patients.
Dr. Flockhart was a pioneer and leader in the field of pharmacogenetics, which involves understanding how an individual’s genes affect his or her response to drugs. Since 2010, he served as the founding director of the Indiana Institute for Personalized Medicine at Indiana University, one of the nation’s first such institutes focused on tailoring treatments for each patient. His research touched nearly every aspect of medicine, from cancer to cardiology, and obstetrics to infectious disease.
“He brought an infectious enthusiasm and a panoramic vision to his work,” said Dr. Patrick J. Loehrer Sr., director of the Indiana University Melvin and Bren Simon Cancer Center and a personal friend. “He wasn’t just about getting grants, but about what could be done to change the face of medicine on a big scale.”
The Hub team